Company: OSRH
Filing Date: 2025-06-23
Form Type: 424B3
Source: 0001213900-25-056351
Chunk: 15

Company: OSR Holdings, Inc.
Filing Date: 2025-06-23
Form: 424B3
Chunk 15
---
 long-term solution.
Additionally, neither symptomatic therapies nor invasive and costly surgical procedures address the underlying cause of chronic and age-related degenerative
diseases. Darnatein’s novel Design Augmented (DA) approach has the potential to overcome these limitations of spine and joint disorders
and osteoarthritis with a regenerative therapy to overcome degeneration in bone and cartilage.

Design-Augmented Biologics Program

In recent years, scientists have studied
the role of bone morphogenetic proteins (BMPs) in healing bone and cartilage. BMPs have been used clinically in orthopedic procedures
but they are typically administered at high, supra-physiological concentrations that have been linked to undesirable local and systemic
side effects. BMPs engineered to have enhanced therapeutic potency may circumvent this problem and provide the desired effects of healing
bone and cartilage while minimizing the likelihood of adverse events.

DRT-101 for Cartilage and Joint
Recovery

DRT-101 is a synthetic bio-signaling molecule
that replaces BMPRII-binding segments of BMP-7, one of the bone-forming proteins, with high affinity ActRII binding segments
of Activin A, a member of the transforming growth factor ß (TGF-ß). In nature, endogenous BMP7 promotes chondrogenesis in
damaged cartilage tissue by signaling primarily via the type II receptor BMPRII and to a lesser extent via the activin type II
receptor ActRII, which it binds with lower affinity. DRT-101 amplifies intracellular regeneration signaling capacity compared to
natural BMP-7 and allows for regeneration and restoration of mechanically depleted cartilage cells to normal levels.

DRT-101 pre-clinical study in animals

DRT-101 was evaluated in Sprague Dawley
rats by ChemOn Inc. in 2021 for toxicity measurement. This study was conducted to assess the approximate lethal dose (ALD) and the dose-range finding(DRF)
of the test substance DRT-101, when administered intravenously.

Information about the clinical trials in connection
with DRT-101 and DRT-102 is set forth under Item 1 of our Current Report on Form 10-K filed with the SEC on April 22, 2025, and incorporated
herein by reference.

<div align='center'>7</div>

RMC Corporate Overview RMC is a Korea-based neurovascular intervention medical device and systems distribution company exclusively serving the Korea market currently